Anidulafungin
- Generic Name
- Anidulafungin
- Brand Names
- Ecalta, Eraxis
- Drug Type
- Small Molecule
- Chemical Formula
- C58H73N7O17
- CAS Number
- 166663-25-8
- Unique Ingredient Identifier
- 9HLM53094I
- Background
Anidulafungin or Eraxis is an anti-fungal drug manufactured by Pfizer that gained approval by the Food and Drug Administration (FDA) in February 21, 2006; it was previously known as LY303366. There is preliminary evidence that it has a similar safety profile to caspofungin.
- Indication
用于治疗食管念珠菌感染，念珠菌性败血症，念珠菌引起的腹腔脓肿及念珠菌性腹膜炎。
- Associated Conditions
- Bloodstream Infections (BSI), Candidemia, Candidiasis, Esophageal Candidiasis, Fungal peritonitis caused by Candida, Intraabdominal Abscess caused by Candida, Invasive Aspergillosis, Oropharyngeal Candidiasis
- Associated Therapies
- -
The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis
Phase 3
Completed
- Conditions
- Candidiasis
- First Posted Date
- 2003-03-12
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 256
- Registration Number
- NCT00056368
- Locations
- 🇺🇸
Versicor, Inc., King of Prussia, Pennsylvania, United States
Safety, Tolerance and Pharmacokinetics of Anidulafungin in Immunocompromised Children Ages 2-17
Phase 1
Completed
- Conditions
- Neutropenia
- First Posted Date
- 2003-03-12
- Last Posted Date
- 2008-10-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 25
- Registration Number
- NCT00056381
- Locations
- 🇺🇸
Versicor, King of Prussia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath